文献速递基础与转化研究新药、器械与细胞基因治疗研发

CRISPR编辑干细胞用于HIV合并急性淋巴细胞白血病患者

CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia.
PubMed 文献 · N Engl J Med · 2019-09-11

该研究将CRISPR编辑的CCR5基因敲除造血干/祖细胞移植入一名HIV-1感染合并急性淋巴细胞白血病患者,移植成功且供者细胞携带敲除的CCR5持续超过19个月,未发生基因编辑相关不良事件;但淋巴细胞中CCR5 disrupted比例仅约5%,作者指出需进一步研究。

要点

  • CRISPR编辑的CCR5敲除造血干/祖细胞移植成功并长期植入,持续超过19个月。
  • 未发生基因编辑相关不良事件,急性淋巴细胞白血病达完全缓解且完全供者嵌合。
  • 淋巴细胞中CCR5 disrupted比例仅约5%,作者指出需进一步研究该策略。

核心结论

  • 成功实现CRISPR编辑造血干/祖细胞的移植和长期植入,但淋巴细胞中CCR5 disrupted比例仅约5%,作者指出需进一步研究该策略。

研究设计与样本

  • 将CRISPR编辑的CCR5基因敲除造血干/祖细胞(HSPCs)移植入一名HIV-1感染合并急性淋巴细胞白血病患者。

主要发现

  • 急性淋巴细胞白血病达完全缓解且完全供者嵌合,携带敲除CCR5的供者细胞持续超过19个月,无基因编辑相关不良事件。
  • 在抗逆转录病毒治疗中断期间,CCR5敲除的CD4+细胞百分比出现小幅度增加。

局限性

  • 淋巴细胞中CCR5 disrupted比例仅约5%,作者指出需进一步研究该策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The safety of CRISPR (clustered regularly interspaced short palindromic repeats)-based genome editing in the context of human gene therapy is largely unknown. CCR5 is a reasonable but not absolutely protective target for a cure of human immunodeficiency virus type 1 (HIV-1) infection, because CCR5-null blood cells are largely resistant to HIV-1 entry. We transplanted CRISPR-edited CCR5-ablated hematopoietic stem and progenitor cells (HSPCs) into a patient with HIV-1 infection and acute lymphoblastic leukemia. The acute lymphoblastic leukemia was in complete remission with full donor chimerism, and donor cells carrying the ablated CCR5 persisted for more than 19 months without gene editing-related adverse events. The percentage of CD4+ cells with CCR5 ablation increased by a small degree during a period of antiretroviral-therapy interruption. Although we achieved successful transplantation and long-term engraftment of CRISPR-edited HSPCs, the percentage of CCR5 disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach. (Funded by the Beijing Municipal Science and Technology Commission and others; ClinicalTrials.gov number, NCT03164135.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Xu L, Wang J, Liu Y, et al. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. N Engl J Med. 2019. PMID: 31509667. doi:10.1056/NEJMoa1817426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。